Abstract
Objective To evaluate the clinical value of epidermal growth factor receptor (EGFR) mutation testing for advanced non-small cell lung cancer (NSCLC) patients. Methods SCI, PubMed, Medline, CBM and CNKI were searched for the literatures about EGFR mutation testing in blood of NSCLC patients.The sensitivity, specificity and symmetric receiver operator characteristic curve were used to evaluate the diagnostic features of EGFR testing in blood. Results The data from 13 studies with 2 349 patients samples were enrolled.The sensitivity and specificity of EGFR mutation testing in blood were 61%(95%CI: 0.49-0.72) and 96%(95%CI: 0.90-0.99). Area under curve was 0.85 (95%CI: 0.82-0.88). Conclusions Blood, especially plasma, can become an effective substitution for EGFR mutation testing for advanced NSCLC patients when it is difficult to obtain tumor tissues. Key words: Meta-analysis; Non-small cell lung cancer; Epidermal growth factor receptor; Blood; Mutation
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call